SCHEMBL7349

SCHEMBL7349

CSc1ccccc1NN

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.47
SMN1; SMN2 Q16637 3/20 0.47
KMT2A Q03164 4/20 0.46
MEN1 O00255 3/20 0.46
POLB P06746 2/20 0.42
TP53 P04637 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
HSD17B10 Q99714 1/20 0.42
MAPT P10636 3/20 0.41
NPC1 O15118 1/20 0.41
LMNA P02545 1/20 0.41
RAB9A P51151 1/20 0.41
MAPK1 P28482 1/20 0.41
PTGES2 Q9H7Z7 1/20 0.41
CA12 O43570 1/20 0.40
CA1 P00915 1/20 0.40
CA2 P00918 1/20 0.40
CA6 P23280 1/20 0.40
CA5A P35218 1/20 0.40
CA7 P43166 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29573636 1.00 ALDH1A1 (0.47) ALDH1A1SMN1; SMN2KMT2AMEN1POLB
Hydrochloric Acid SCHEMBL29573589 0.98 ALDH1A1 (0.46) ALDH1A1SMN1; SMN2KMT2AMEN1POLB
Hydrochloric Acid SCHEMBL1843712 0.98 ALDH1A1 (0.46) ALDH1A1SMN1; SMN2KMT2AMEN1POLB
SCHEMBL27993335 0.84 CETP (0.39) ALDH1A1SMN1; SMN2KMT2AMEN1POLB
SCHEMBL31231922 0.79 ALDH1A1 (0.50) ALDH1A1SMN1; SMN2KMT2AMEN1POLB
SCHEMBL23302280 0.78 ADRA2A (0.45) ALDH1A1POLBHSD17B10MAPTMAPK1
SCHEMBL8495606 0.77 ALDH1A1 (0.48) ALDH1A1SMN1; SMN2KMT2AMEN1POLB
Hydrochloric Acid SCHEMBL7026748 0.77 ALDH1A1 (0.42) ALDH1A1SMN1; SMN2KMT2AMEN1POLB
Hydrochloric Acid SCHEMBL23302378 0.76 ADRA2A (0.47) ALDH1A1SMN1; SMN2KMT2AMEN1POLB
SCHEMBL23875800 0.75 KMT2A (0.50) ALDH1A1SMN1; SMN2KMT2AMEN1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3807266-B1 PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2023-10-25 EP disclosed
EP-3807266-B1 PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2023-10-25 EP disclosed
CN-112585128-B Pyrazole derivatives as MALT1 inhibitors 詹森药业有限公司 2023-02-21 CN disclosed
WO-2022040157-A1 BORON CONTAINING COMPOUNDS AND THEIR USES 5METIS, INC. (US) 2022-02-24 WO disclosed
WO-2022040157-A1 BORON CONTAINING COMPOUNDS AND THEIR USES 5METIS, INC. (US) 2022-02-24 WO disclosed
US-11040031-B2 Pyrazole derivatives as MALT1 inhibitors JANSSEN PHARMACEUTICA NV (BE) 2021-06-22 US disclosed
US-11040031-B2 Pyrazole derivatives as MALT1 inhibitors JANSSEN PHARMACEUTICA NV (BE) 2021-06-22 US disclosed
EP-3807266-A1 PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS Janssen Pharmaceutica N.V. (BE) 2021-04-21 EP disclosed
CN-112585128-A Pyrazole derivatives as MALT1 inhibitors 詹森药业有限公司 2021-03-30 CN disclosed
EP-3756464-A1 SUBSTITUTED OXADIAZOLES FOR COMBATING PHYTOPATHOGENIC FUNGI BASF SE (DE) 2020-12-30 EP disclosed
US-20010047027-A1 Prostaglandin D2 receptor antagonists LABELLE MARC (US) 2001-11-29 US disclosed
WO-2001078697-A2 METHOD AND COMPOSITIONS FOR THE TREATMENT OF ALLERGIC CONDITIONS USING PGD2 RECEPTOR ANTAGONISTS MERCK FROSST CANADA & CO. (CA) 2001-10-25 WO disclosed
WO-2001079169-A2 PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS MERCK FROSST CANADA & CO. (CA) 2001-10-25 WO disclosed
US-6291470-B1 DELTA-OPIOID ANTAGONIST HAVING HIGH SELECTIVITY AND ACTIVITY, THAT EXHIBITS IMMUNOSUPPRESSIVE ACTION, ANTIALLERGIC ACTION, ANTI-INFLAMMATORY ACTION AND BRAIN CELL-PROTECTING ACTION TORAY INDUSTRIES, INC. (JP) 2001-09-18 US disclosed
US-6087369-A AN IMMUNOSUPPRESSIVE AGENT, ANTIALLERGIC AGENT, ANTI-INFLAMMATORY AGENT AND BRAIN CELL-PROTECTING AGENT TORAY INDUSTRIES, LTD. (JP) 2000-07-11 US disclosed
US-5852030-A Indole derivatives, process for producing the same and medicinal uses of the same TORAY INDUSTRIES, INC. (JP) 1998-12-22 US disclosed
EP-0614898-A1 INDOLE DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND MEDICINAL USE THEREOF TORAY INDUSTRIES, INC. (JP) 1994-09-14 EP disclosed
US-5081138-A Antiasthmatic, antiallergic, antiinflammatory and cytoprotective agents MERCK FROSST CANADA, INC. (CA) 1992-01-14 US disclosed
US-4448961-A Substituted anilino pyrimidines ZOECON CORPORATION (US) 1984-05-15 US disclosed
US-4411839-A α-Cyano-β-(trisubstituted phenylhydrazino)-n-ethoxycarbonylacrylamides ZOECON CORPORATION (US) 1983-10-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11040031-B2 Pyrazole derivatives as MALT1 inhibitors MALT1, PPP3R1, SQSTM1 ALDH1A1 2534/4885SMN1; SMN2 2443/4885KMT2A 3356/4885
US-20010047027-A1 Prostaglandin D2 receptor antagonists PTGDR2, PTGDR, LTB4R2 ALDH1A1 477/4885SMN1; SMN2 4842/4885KMT2A 3963/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.